• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Dexcom Inc (NQ: DXCM )

    65.38 -42.47 (-39.38%)
    Streaming Delayed Price Updated: 9:55 AM EDT, Jul 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Dexcom Inc

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    20 21 Next >
    DexCom Is 'Expanding Rapidly' With Multi-Year Runway Ahead, Bullish Analyst Says
    DexCom Inc’s (NASDAQ: DXCM) Stelo Glucose Biosensor System has been approved by the Food and Drug Administration (FDA) as the first over-the-counter (OTC) 
    Via Benzinga
    Analyst Expectations For DexCom's Future
    Via Benzinga
    Tandem Diabetes Care Stock Belongs On Your Watchlist As RS Rating Jump Higher
    On Monday, Tandem Diabetes Care stock received an upgrade to its Relative Strength (RS) Rating, from 68 to 78. 
    Via Investor's Business Daily
    ServiceNow Setting Up As Three Stocks Flash Buy Signals
    All four stocks to watch boast solid earnings growth. 
    Via Investor's Business Daily
    2 Medical Device Stocks to Buy Hand Over Fist in March
    Don't let their modest gains over the past year mislead you; these stocks can make for great long-term investments. 
    Via The Motley Fool
    Palantir Technologies, SL Green Realty And A Healthcare Stock On CNBC's 'Final Trades'
    On CNBC’s "Halftime Report Final Trades," Jenny Harrington of Gilman Hill Asset Management named SL Green Realty Corp. 
    Via Benzinga
    NASDAQ:DXCM qualifies as a high growth stock and is consolidating.
    Exploring the Growth Potential of DEXCOM INC (NASDAQ:DXCM) as It Nears a Breakout. 
    Via Chartmill
    Here's How Much $100 Invested In DexCom 15 Years Ago Would Be Worth Today
    Via Benzinga
    DexCom: Q4 Earnings Insights
    Via Benzinga
    FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott's
    FDA greenlights DexCom's Stelo, the first OTC continuous glucose monitor for non-insulin-dependent diabetics. Competitive pricing, potential HSA benefits, and market expansion make it a significant... 
    Via Benzinga
    Exposures Product Safety
    Stocks Surge, Gold Hits New All-Time High, Bitcoin Reclaims $67,000 As Powell Reassures Wall Street: What's Driving Markets Wednesday?
    Markets rallied across the board on Wednesday, erasing the uptick in volatility seen in the previous session, following reassurances from Fed Chair Jerome Powell regarding the Fed’s willingness to ease... 
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Why Dexcom — And The Obesity Market — Could Benefit From This New FDA Win
    The FDA granted Dexcom's Stelo a broad clearance, meaning people without diabetes can use it. 
    Via Investor's Business Daily
    Exposures Product Safety
    Prediction: 2 Stocks That Could Trounce the Market
    They have done it before. 
    Via The Motley Fool
    Earnings Scheduled For February 8, 2024
    Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million. 
    Via Benzinga
    If You Invested $100 In This Stock 15 Years Ago, You Would Have $13,000 Today
    Via Benzinga
    FDA Approves Dexcom's Stelo As First Glucose Monitoring Device Without Prescription
    FDA-approved Dexcom Stelo: Over-the-counter glucose monitoring for non-insulin users. Stelo, the first OTC CGM, available online without prescription from summer 2024. Continuous glucose tracking with... 
    Via Benzinga
    Exposures Product Safety
    Campbell Soup, Box And 3 Stocks To Watch Heading Into Wednesday
    With U.S. stock futures trading mostly higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: 
    Via Benzinga
    Adding $1,000 to These Top Growth Stocks Would Be a Brilliant Move
    With patience, these stocks will provide outsized returns to investors. 
    Via The Motley Fool
    Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla
    U.S. stock market continues bull run, hitting record highs for S&P 500 and Nasdaq 100. SPY ETF surpasses $500 billion AUM, with other companies also reaching milestones. 
    Via Benzinga
    Topics ETFs Stocks
    Exposures US Equities
    3 Telehealth Stocks With Room to Run in 2024
    Embrace 2024's leading telehealth stocks to buy, merging cutting-edge care with smart investing for a lucrative portfolio. 
    Via InvestorPlace
    DexCom: A Winner In Diabetes Management
    Diabetes management and glucose monitoring solutions provider DexCom, Inc. recently released its fourth-quarter results, reporting $1.0 billion in revenue, up 27% year-over-year compared to $820... 
    Via Talk Markets
    Got $1,000? Buy These Hot Growth Stocks Before They Take Off
    If you have just $1,000 to spare, you can scoop up shares of these growth stocks before their prices explode. 
    Via The Motley Fool
    Xylem, DexCom And 2 Other Stocks Insiders Are Selling
    The Nasdaq 100 closed lower by around 0.4% on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
    Via Benzinga
    7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution
    Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive. 
    Via InvestorPlace
    These 2 Growth Stocks Could Soar 33% and 45% According to Wall Street Analysts. Are They Smart Buys Now?
    Expectations are high for companies making blood sugar monitors and business automation software. 
    Via The Motley Fool
    Wall Street's Next Stock-Split Stocks Are Liable to Be Familiar Names
    Nine high-profile stocks -- Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk -- have split since mid-2021. Two of these companies appear ready... 
    Via The Motley Fool
    2 No-Brainer Healthcare Stocks to Buy Right Now
    Companies in the healthcare industry tend to generate returns in a wide range of market environments. 
    Via The Motley Fool
    Continuous Glucose Monitor Maker Dexcom's Q4 Profit Triples On Volume Growth And New Customer Additions
    Dexcom's Q4 2023 performance, reporting $1.03 billion sales, $256.3 million profits, and beating estimates. Dexcom projects $4.15-$4.35 billion in 2024 revenues. William Blair affirms Outperform... 
    Via Benzinga
    DexCom (DXCM) Q4 2023 Earnings Call Transcript
    DXCM earnings call for the period ending December 31, 2023. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    2 Phenomenal Stocks to Buy for the New Year
    These growth stocks are raking in profits and cash as leaders in their respective industries. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    20 21 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.